Article info
PDFColorectal
Original research
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response
- Correspondence to Dr Mark A Samaan, IBD Centre, Guy's and Saint Thomas' NHS Foundation Trust, London SE1 7EH, UK; markasamaan{at}gmail.com
Citation
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response
Publication history
- Received May 9, 2019
- Revised June 26, 2019
- Accepted June 27, 2019
- First published July 11, 2019.
Online issue publication
May 23, 2020
Article Versions
- Previous version (23 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.